» Articles » PMID: 31797235

Whole Brain Apparent Diffusion Coefficient Measurements Correlate with Survival in Glioblastoma Patients

Overview
Journal J Neurooncol
Publisher Springer
Date 2019 Dec 5
PMID 31797235
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Glioblastoma (GBM) is the most common malignant primary brain tumor, and methods to improve the early detection of disease progression and evaluate treatment response are highly desirable. We therefore explored changes in whole-brain apparent diffusion coefficient (ADC) values with respect to survival (progression-free [PFS], overall [OS]) in a cohort of GBM patients followed at regular intervals until disease progression.

Methods: A total of 43 subjects met inclusion criteria and were analyzed retrospectively. Histogram data were extracted from standardized whole-brain ADC maps including skewness, kurtosis, entropy, median, mode, 15th percentile (p15) and 85th percentile (p85) values, and linear regression slopes (metrics versus time) were fitted. Regression slope directionality (positive/negative) was subjected to univariate Cox regression. The final model was determined by aLASSO on metrics above threshold.

Results: Skewness, kurtosis, median, p15 and p85 were all below threshold for both PFS and OS and were analyzed further. Median regression slope directionality best modeled PFS (p = 0.001; HR 3.3; 95% CI 1.6-6.7), while p85 was selected for OS (p = 0.002; HR 0.29; 95% CI 0.13-0.64).

Conclusions: Our data show tantalizing potential in the use of whole-brain ADC measurements in the follow up of GBM patients, specifically serial median ADC values which correlated with PFS, and serial p85 values which correlated with OS. Whole-brain ADC measurements are fast and easy to perform, and free of ROI-placement bias.

Citing Articles

Anti-glioblastoma effects of phenolic variants of benzoylphenoxyacetamide (BPA) with high potential for blood brain barrier penetration.

Stalinska J, Vittori C, Ingraham Iv C, Carson S, Plaisance-Bonstaff K, Lassak A Sci Rep. 2022; 12(1):3384.

PMID: 35232976 PMC: 8888627. DOI: 10.1038/s41598-022-07247-8.


Glioma-Specific Diffusion Signature in Diffusion Kurtosis Imaging.

Hempel J, Brendle C, Adib S, Behling F, Tabatabai G, Vega S J Clin Med. 2021; 10(11).

PMID: 34073442 PMC: 8199055. DOI: 10.3390/jcm10112325.


Simvastatin Induces Unfolded Protein Response and Enhances Temozolomide-Induced Cell Death in Glioblastoma Cells.

Dastghaib S, Shojaei S, Mostafavi-Pour Z, Sharma P, Patterson J, Samali A Cells. 2020; 9(11).

PMID: 33105603 PMC: 7690447. DOI: 10.3390/cells9112339.


Predicting Survival in Glioblastoma Patients Using Diffusion MR Imaging Metrics-A Systematic Review.

Brancato V, Nuzzo S, Tramontano L, Condorelli G, Salvatore M, Cavaliere C Cancers (Basel). 2020; 12(10).

PMID: 33020420 PMC: 7600641. DOI: 10.3390/cancers12102858.

References
1.
Khalifa J, Tensaouti F, Lotterie J, Catalaa I, Chaltiel L, Benouaich-Amiel A . Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation?. J Neurooncol. 2016; 130(1):181-192. DOI: 10.1007/s11060-016-2232-8. View

2.
Lu W, Zhang H . Variable selection for proportional odds model. Stat Med. 2007; 26(20):3771-81. DOI: 10.1002/sim.2833. View

3.
Tykocki T, Eltayeb M . Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci. 2018; 54:7-13. DOI: 10.1016/j.jocn.2018.05.002. View

4.
Cordova J, Shu H, Liang Z, Gurbani S, Cooper L, Holder C . Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients. Neuro Oncol. 2016; 18(8):1180-9. PMC: 4933486. DOI: 10.1093/neuonc/now036. View

5.
Kondo M, Uchiyama Y . Apparent diffusion coefficient histogram analysis for prediction of prognosis in glioblastoma. J Neuroradiol. 2017; 45(4):236-241. DOI: 10.1016/j.neurad.2017.11.011. View